Treating the mind can improve blood sugar—and some diabetes drugs may also lift mood. Here’s what the latest evidence says.

A state‑of‑the‑art review in Translational Psychiatry (2025) pulls together decades of research and delivers a practical message: depression and diabetes commonly occur together, worsen each other’s outcomes, and need joined‑up carerather than siloed treatment. The authors outline how shared drivers—sleep disruption, inactivity, diet, chronic stress, and some genetic and social factors—raise risk for both, and why addressing only one condition often falls short.

What’s new (and useful) for patients and clinicians

• Treating depression helps diabetes care. When depressive symptoms improve, people are more likely to take medications, monitor glucose, and engage in activity—habits that lower A1c and complications. The review urges routine depression screening in diabetes visits and close follow‑up when starting or changing mood treatments.
• Antidepressants: mind the metabolism.
  • Some SSRIs have been linked to small increases in type 2 diabetes risk with long‑term use (evidence is mixed, especially in youth).
  • Effects on glucose control vary by drug: certain serotonergic agents may slightly lower glucose; noradrenergic agents have been tied to higher glucose in some reports; SNRIs (e.g., duloxetine) appear largely neutral on average.
  • Adjunct atypical antipsychotics (e.g., olanzapine, quetiapine) can promote weight gain and metabolic side effects.Bottom line: monitor weight, lipids, and blood sugar after starting or adjusting antidepressants—especially in people with diabetes.
• Diabetes medicines and mood:
  • GLP‑1 receptor agonists (e.g., semaglutide, liraglutide) are “game‑changers” for diabetes and weight. Early studies on depression are mixed: some show symptom improvements; others don’t. Regulators reviewed safety signals about suicidal thoughts—Europe’s EMA (Apr 2024) found no causal link, while the U.S. FDA (Jan 2024) is still analyzing and labels advise monitoring mood.
  • SGLT2 inhibitors have intriguing early data: large population studies suggest lower depression risk, and a small trial found empagliflozin added to citalopram improved depressive symptoms—findings that need larger, longer trials.
  • Pioglitazone shows inconsistent antidepressant benefits and carries weight gain/edema risks; metformin’smood effects remain uncertain.
• Therapies that travel well: Cognitive‑behavioral therapy, mindfulness, and acceptance/commitment therapy, delivered in clinics or digitally, reduce “diabetes distress” and support long‑term self‑care.

The take‑home

• Ask for integrated care: mental‑health screening at diabetes visits, coordinated plans between primary care, endocrinology, and behavioral health, and clear goals you help set.
• If you start a new antidepressant or diabetes drug, plan a glucose and mood check‑in within weeks—sooner if you notice changes in appetite, sleep, energy, or thoughts of self‑harm.
• Lifestyle still matters: sleep, movement, nutritious meals, and social support remain powerful, low‑risk treatments that strengthen both metabolic and mental health.

Source: Fanelli G, Lunghi C, Raschi E, et al. “The interface of depression and diabetes: treatment considerations.”Translational Psychiatry. 2025;15:22. doi: 10.1038/s41398-025-03234-5.